EA201690731A1 - Анализ igfbp7, имеющий улучшенную характеристику в биологических образцах - Google Patents
Анализ igfbp7, имеющий улучшенную характеристику в биологических образцахInfo
- Publication number
- EA201690731A1 EA201690731A1 EA201690731A EA201690731A EA201690731A1 EA 201690731 A1 EA201690731 A1 EA 201690731A1 EA 201690731 A EA201690731 A EA 201690731A EA 201690731 A EA201690731 A EA 201690731A EA 201690731 A1 EA201690731 A1 EA 201690731A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- analysis
- igfbp7
- improved characteristics
- biological specimens
- improved
- Prior art date
Links
- 238000004458 analytical method Methods 0.000 title abstract 3
- 101000840577 Homo sapiens Insulin-like growth factor-binding protein 7 Proteins 0.000 title abstract 2
- 102100029228 Insulin-like growth factor-binding protein 7 Human genes 0.000 title abstract 2
- 239000013060 biological fluid Substances 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 238000010324 immunological assay Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4745—Insulin-like growth factor binding protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361900942P | 2013-11-06 | 2013-11-06 | |
| US201462054324P | 2014-09-23 | 2014-09-23 | |
| US201462064380P | 2014-10-15 | 2014-10-15 | |
| PCT/US2014/064327 WO2015069880A1 (en) | 2013-11-06 | 2014-11-06 | Assays for igfbp7 having improved performance in biological samples |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201690731A1 true EA201690731A1 (ru) | 2016-10-31 |
Family
ID=53042071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201690731A EA201690731A1 (ru) | 2013-11-06 | 2014-11-06 | Анализ igfbp7, имеющий улучшенную характеристику в биологических образцах |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9822172B2 (OSRAM) |
| EP (2) | EP3556863B1 (OSRAM) |
| JP (4) | JP2017501211A (OSRAM) |
| KR (1) | KR102404285B1 (OSRAM) |
| CN (1) | CN105793439B (OSRAM) |
| AU (1) | AU2014346695B2 (OSRAM) |
| BR (1) | BR112016010106A2 (OSRAM) |
| CA (2) | CA3185700A1 (OSRAM) |
| EA (1) | EA201690731A1 (OSRAM) |
| HK (1) | HK1221490A1 (OSRAM) |
| MX (1) | MX375701B (OSRAM) |
| WO (1) | WO2015069880A1 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010048346A1 (en) | 2008-10-21 | 2010-04-29 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| ES2818138T3 (es) | 2009-12-20 | 2021-04-09 | Astute Medical Inc | Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal |
| EP2585827A4 (en) | 2010-06-23 | 2013-12-04 | Astute Medical Inc | METHOD AND COMPOSITIONS FOR DIAGNOSIS AND FORECASTING kidney injury and kidney insufficiency |
| EP3540440B1 (en) | 2011-12-08 | 2022-09-28 | Astute Medical, Inc. | Methods and uses for evaluating renal injury and renal status |
| JP6681195B2 (ja) | 2013-01-17 | 2020-04-15 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
| JP2016540759A (ja) | 2013-12-03 | 2016-12-28 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後のための方法および組成物 |
| US11243202B2 (en) | 2015-04-09 | 2022-02-08 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN108139409B (zh) * | 2015-10-08 | 2020-07-24 | 豪夫迈·罗氏有限公司 | 当在外科手术之前测量时用于预测aki的风险的igfbp7 |
| EP3465201A4 (en) | 2016-06-06 | 2020-08-26 | Astute Medical, Inc. | MANAGEMENT OF ACUTE KIDNEY DAMAGE USING INSULINOMIMETIC GROWTH FACTOR BINDING PROTEIN 7 AND TISSUE METALLOPROTEINASE 2 INHIBITOR |
| CN110431422A (zh) | 2017-02-06 | 2019-11-08 | 机敏医药股份有限公司 | 用于肾损伤和肾衰竭的诊断和预后的方法和组合物 |
| US11718682B2 (en) | 2017-04-05 | 2023-08-08 | Astute Medical, Inc. | Assays for TIMP2 having improved performance in biological samples |
| CN112384807A (zh) | 2018-05-24 | 2021-02-19 | 雷尼布斯治疗公司 | 治疗有风险患有肾损伤和肾衰竭的患者的方法 |
| WO2020234482A1 (en) * | 2019-05-21 | 2020-11-26 | Universität Zürich | MAPKi RESISTANCE SIGNATURES |
| KR102533791B1 (ko) * | 2022-09-15 | 2023-05-18 | 경북대학교 산학협력단 | 비색법 신호형질 복합체, 이를 이용하는 신장질환 진단용 키트 및 진단법 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3029579C2 (de) | 1980-08-05 | 1985-12-12 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren und Mittel zur Abtrennung von Plasma oder Serum aus Vollblut |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5939272A (en) | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
| US5028535A (en) | 1989-01-10 | 1991-07-02 | Biosite Diagnostics, Inc. | Threshold ligand-receptor assay |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| ATE356869T1 (de) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
| US5922615A (en) | 1990-03-12 | 1999-07-13 | Biosite Diagnostics Incorporated | Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network |
| US5166051A (en) | 1990-08-08 | 1992-11-24 | Genesis Labs, Inc. | Membranes, membrane overlays for exclusion of erythrocytes, and method for immunoassay of whole blood analytes |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| WO1992005282A1 (en) | 1990-09-14 | 1992-04-02 | Biosite Diagnostics, Inc. | Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays |
| GB9109645D0 (en) * | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
| US5955377A (en) | 1991-02-11 | 1999-09-21 | Biostar, Inc. | Methods and kits for the amplification of thin film based assays |
| FI934437L (fi) | 1991-04-10 | 1993-11-22 | Biosite Diagnostics Inc | Crosstalk-inhibitorer och deras anvaendning |
| CA2107899A1 (en) | 1991-04-10 | 1992-10-11 | Gunars Edwin Valkirs | Novel conjugates and assays for simultaneous detection of multiple ligands |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US6143576A (en) | 1992-05-21 | 2000-11-07 | Biosite Diagnostics, Inc. | Non-porous diagnostic devices for the controlled movement of reagents |
| US6019944A (en) | 1992-05-21 | 2000-02-01 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membranes |
| US5494829A (en) | 1992-07-31 | 1996-02-27 | Biostar, Inc. | Devices and methods for detection of an analyte based upon light interference |
| US5824799A (en) | 1993-09-24 | 1998-10-20 | Biosite Diagnostics Incorporated | Hybrid phthalocyanine derivatives and their uses |
| ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6391265B1 (en) | 1996-08-26 | 2002-05-21 | Biosite Diagnostics, Inc. | Devices incorporating filters for filtering fluid samples |
| US6113855A (en) | 1996-11-15 | 2000-09-05 | Biosite Diagnostics, Inc. | Devices comprising multiple capillarity inducing surfaces |
| EP2314625B1 (en) | 1996-12-03 | 2014-05-07 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| US6045899A (en) | 1996-12-12 | 2000-04-04 | Usf Filtration & Separations Group, Inc. | Highly assymetric, hydrophilic, microfiltration membranes having large pore diameters |
| US5947124A (en) | 1997-03-11 | 1999-09-07 | Biosite Diagnostics Incorporated | Diagnostic for determining the time of a heart attack |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| US7109030B2 (en) * | 2000-03-31 | 2006-09-19 | Nuvelo, Inc. | Methods of therapy and diagnosis using insulin-like growth factor binding protein-like polypeptides and polynucleotides |
| US20020132983A1 (en) | 2000-11-30 | 2002-09-19 | Junghans Richard P. | Antibodies as chimeric effector cell receptors against tumor antigens |
| JP2008541017A (ja) * | 2005-04-29 | 2008-11-20 | ベックマン コールター インコーポレイテッド | 側方流動蛍光免疫測定法 |
| BRPI0613387A2 (pt) | 2005-07-08 | 2011-01-11 | Biogen Idec Inc | anticorpo isolado ou fragmento de ligação de antìgeno deste e o seu uso, polinucleotìdeo isolado, composição, vetor, célula hospedeira, anticorpo anti-sp35 e método para a produção do mesmo, polipeptìdeo isolado, método in vitro para redução da inibição do crescimento axonal e método in vitro para inibição do crescimento do colapso do cone |
| WO2008089994A1 (en) * | 2007-01-25 | 2008-07-31 | Roche Diagnostics Gmbh | Use of igfbp-7 in the assessment of heart failure |
| CA2740134C (en) * | 2008-10-14 | 2021-10-26 | National Research Council Of Canada | Formulations targeting igfbp7 for diagnosis and therapy of cancer |
| WO2010127294A2 (en) | 2009-05-01 | 2010-11-04 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
| ES2818138T3 (es) | 2009-12-20 | 2021-04-09 | Astute Medical Inc | Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal |
| EP2666872B1 (en) | 2010-02-05 | 2016-04-27 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| RU2013113638A (ru) * | 2010-08-27 | 2014-10-10 | Стем Сентркс, Инк. | МОДУЛЯТОРЫ БЕЛКА Notum И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| CN104870011A (zh) * | 2011-11-03 | 2015-08-26 | 托莱拉医疗股份有限公司 | 选择性抑制t细胞应答的抗体和方法 |
-
2014
- 2014-11-06 WO PCT/US2014/064327 patent/WO2015069880A1/en not_active Ceased
- 2014-11-06 CA CA3185700A patent/CA3185700A1/en active Pending
- 2014-11-06 US US15/035,205 patent/US9822172B2/en active Active
- 2014-11-06 EP EP19158290.7A patent/EP3556863B1/en active Active
- 2014-11-06 BR BR112016010106A patent/BR112016010106A2/pt not_active Application Discontinuation
- 2014-11-06 HK HK16109610.3A patent/HK1221490A1/zh unknown
- 2014-11-06 KR KR1020167014700A patent/KR102404285B1/ko active Active
- 2014-11-06 EP EP14860878.9A patent/EP3066221A4/en not_active Withdrawn
- 2014-11-06 MX MX2016005834A patent/MX375701B/es active IP Right Grant
- 2014-11-06 JP JP2016552481A patent/JP2017501211A/ja active Pending
- 2014-11-06 EA EA201690731A patent/EA201690731A1/ru unknown
- 2014-11-06 CN CN201480066318.8A patent/CN105793439B/zh active Active
- 2014-11-06 CA CA2929547A patent/CA2929547C/en active Active
- 2014-11-06 AU AU2014346695A patent/AU2014346695B2/en active Active
-
2017
- 2017-11-20 US US15/818,669 patent/US10562961B2/en active Active
-
2019
- 2019-11-25 JP JP2019212462A patent/JP2020048569A/ja active Pending
-
2020
- 2020-01-17 US US16/745,781 patent/US20200247879A1/en not_active Abandoned
-
2022
- 2022-01-13 JP JP2022003920A patent/JP7277623B2/ja active Active
-
2023
- 2023-01-06 JP JP2023000938A patent/JP2023052239A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20160289308A1 (en) | 2016-10-06 |
| MX375701B (es) | 2025-03-06 |
| US20200247879A1 (en) | 2020-08-06 |
| US20180066045A1 (en) | 2018-03-08 |
| CA3185700A1 (en) | 2015-05-14 |
| CN105793439A (zh) | 2016-07-20 |
| US9822172B2 (en) | 2017-11-21 |
| EP3066221A1 (en) | 2016-09-14 |
| HK1221490A1 (zh) | 2017-06-02 |
| JP2020048569A (ja) | 2020-04-02 |
| JP2023052239A (ja) | 2023-04-11 |
| CN105793439B (zh) | 2020-09-04 |
| KR102404285B1 (ko) | 2022-05-31 |
| KR20160068988A (ko) | 2016-06-15 |
| US10562961B2 (en) | 2020-02-18 |
| CA2929547A1 (en) | 2015-05-14 |
| JP2017501211A (ja) | 2017-01-12 |
| JP7277623B2 (ja) | 2023-05-19 |
| AU2014346695B2 (en) | 2020-10-15 |
| BR112016010106A2 (pt) | 2017-12-05 |
| EP3066221A4 (en) | 2017-09-20 |
| EP3556863A1 (en) | 2019-10-23 |
| WO2015069880A1 (en) | 2015-05-14 |
| AU2014346695A1 (en) | 2016-06-16 |
| CA2929547C (en) | 2023-02-28 |
| JP2022068143A (ja) | 2022-05-09 |
| MX2016005834A (es) | 2016-11-17 |
| EP3556863B1 (en) | 2024-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201690731A1 (ru) | Анализ igfbp7, имеющий улучшенную характеристику в биологических образцах | |
| EA201690185A1 (ru) | Анализ timp2, обладающий улучшенной эффективностью в биологическом образце | |
| CL2015002756A1 (es) | Moléculas fc biespecíficas | |
| MX377956B (es) | Sistemas y métodos para maximización de uso de muestras. | |
| BR112015022490A2 (pt) | métodos e composições para classificação de amostras | |
| MX374652B (es) | Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco. | |
| BR112015007672A2 (pt) | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso | |
| WO2014144822A3 (en) | Methods and compositions for tagging and analyzing samples | |
| BR112016014022A2 (pt) | anticorpos anti-cd3, ácido nucleico isolado, vetor, célula hospedeira, método de produção do anticorpo anti-cd3, imunoconjugado, composição, uso do anticorpo anti-cd3, métodos de tratamento, métodos de intensificação da função imune e kit | |
| EP2953643A4 (en) | NON-PLATE DEPLETING AND NON-ERYTHROCYTE DEPLETING CD47 ANTIBODIES AND METHOD FOR USE THEREOF | |
| EA201690617A1 (ru) | Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей | |
| EA201491599A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| MX377772B (es) | Inmunoensayo de canalización de oxígeno luminiscente utilizando tres anticuerpos y metodos de produccion y uso de los mismos. | |
| BR112014008382A2 (pt) | anticorpo especificamente ligando a epítope no domínio sema do c-met | |
| AR093984A1 (es) | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano | |
| MX366275B (es) | Metodos para detectar y medir la agregacion. | |
| MX362075B (es) | Ensayo de combinación de antígeno-anticuerpo del virus de la hepatitis c (vhc) y métodos y composiciones para usarlo. | |
| UY34999A (es) | Formulaciones de anticuerpos anti-receptor de prolactina | |
| EA201792289A1 (ru) | Способы обнаружения агглютинации и композиции для их осуществления | |
| EA201890078A1 (ru) | Антитело | |
| IN2014DN08011A (OSRAM) | ||
| EA201400873A1 (ru) | Механическая промывка и измерительный прибор для выполнения анализов | |
| BR112016017764A2 (pt) | anticorpo antidengue de amplo espectro | |
| EA201991506A1 (ru) | Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов | |
| PE20160657A1 (es) | Composiciones y metodos para identificar un riesgo de cancer en un sujeto |